ArticleFuture oncology (London, England)Published
Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS
Regional connection
Verified Author affiliations on the Europe PMC record name Perelman School of Medicine, University of Pennsylvania. Affiliation source
- Institutions
- Perelman School of Medicine, University of Pennsylvania
- County
- Philadelphia County
Publication record
- Type
- Article
- Venue
- Future oncology (London, England)
- Published
- Topic
- Clinical care
- Subject terms
- Humans; Liposarcoma; Doxorubicin; Tumor Suppressor Protein p53; Proto-Oncogene Proteins c-mdm2; Multicenter Studies as Topic; Clinical Trials, Phase III as Topic; doxorubicin; Dedifferentiated Liposarcoma; Phase Ii/iii Trial; Bi 907828; Mdm2–p53 Antagonist
- PubMed ID
- 36987836
- Added to directory
- Source checked